Astrogen signs $208.5 million deal to supply autism treatment material in Middle East

Astrogen, a Korean clinical-stage pharmaceutical company, said Wednesday it has signed a $208.5 million deal with a Middle Eastern company to supply a therapeutic material for treating the core symptoms of autism spectrum disorder (ASD).